These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 29291705

  • 1. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T, Yoshioka H, Tamiya M, Tamiya A, Hata A, Okada A, Niwa T, Shiroyama T, Kanazu M, Ishida T, Katakami N.
    BMC Cancer; 2018 Jan 02; 18(1):6. PubMed ID: 29291705
    [Abstract] [Full Text] [Related]

  • 2. [Association between Efficacy of Pemetrexed and EGFR Mutation Status for EGFR Mutated Lung Carcinoma].
    Kogure Y, Saka H, Imaizumi K.
    Gan To Kagaku Ryoho; 2016 Jun 02; 43(6):733-5. PubMed ID: 27306810
    [Abstract] [Full Text] [Related]

  • 3. Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
    Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N.
    Cancer Sci; 2015 Sep 02; 106(9):1202-11. PubMed ID: 26094656
    [Abstract] [Full Text] [Related]

  • 4. EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Nonsquamous Nonsmall Cell Lung Cancer.
    Igawa S, Sato Y, Ishihara M, Kasajima M, Kusuhara S, Nakahara Y, Otani S, Fukui T, Katagiri M, Sasaki J, Masuda N.
    Asian Pac J Cancer Prev; 2016 Sep 02; 17(7):3249-53. PubMed ID: 27509958
    [Abstract] [Full Text] [Related]

  • 5. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T, Hata A, Tomioka H, Tanaka K, Kaji R, Fujita S, Tomii K, Katakami N.
    Lung Cancer; 2014 Nov 02; 86(2):213-8. PubMed ID: 25304185
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
    Wang Y, Li RQ, Ai YQ, Zhang J, Zhao PZ, Li YF, He WJ, Xia YX, Li WH.
    Clin Transl Oncol; 2015 Sep 02; 17(9):727-36. PubMed ID: 26041721
    [Abstract] [Full Text] [Related]

  • 8. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.
    Clin Transl Oncol; 2017 Mar 02; 19(3):317-325. PubMed ID: 27492015
    [Abstract] [Full Text] [Related]

  • 9. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.
    Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC.
    J Clin Oncol; 2017 Dec 20; 35(36):4027-4034. PubMed ID: 28968167
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
    Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF, Swiss Group for Clinical Cancer Research.
    Clin Lung Cancer; 2015 Sep 20; 16(5):358-65. PubMed ID: 25843489
    [Abstract] [Full Text] [Related]

  • 12. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.
    Shi YK, Wang L, Han BH, Li W, Yu P, Liu YP, Ding CM, Song X, Ma ZY, Ren XL, Feng JF, Zhang HL, Chen GY, Han XH, Wu N, Yao C, Song Y, Zhang SC, Song W, Liu XQ, Zhao SJ, Lin YC, Ye XQ, Li K, Shu YQ, Ding LM, Tan FL, Sun Y.
    Ann Oncol; 2017 Oct 01; 28(10):2443-2450. PubMed ID: 28945850
    [Abstract] [Full Text] [Related]

  • 13. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
    Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M.
    J Clin Oncol; 2013 Sep 20; 31(27):3327-34. PubMed ID: 23816960
    [Abstract] [Full Text] [Related]

  • 14. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH, Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, Liu J, Shek TW, Kwong DL, Leung TW, Wong MP.
    J Thorac Oncol; 2013 Sep 20; 8(9):1148-55. PubMed ID: 23945384
    [Abstract] [Full Text] [Related]

  • 15. An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
    Novello S, Scagliotti G, de Castro G, Kiyik M, Kowalyszyn R, Deppermann KM, Arriola E, Bosquee L, Novosiadly RD, Nguyen TS, Forest A, Tang S, Kambhampati SRP, Cosaert J, Reck M.
    J Thorac Oncol; 2017 Feb 20; 12(2):383-389. PubMed ID: 27464970
    [Abstract] [Full Text] [Related]

  • 16. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A, Takeshita J, Otsuka K, Nishino K, Uchida J, Okuyama T, Namba Y, Mori M, Fujita S, Morita S.
    Lung Cancer; 2015 Sep 20; 89(3):301-5. PubMed ID: 26141215
    [Abstract] [Full Text] [Related]

  • 17. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y, Wu D, Lou Y, Zhang X, Wang H, Han B.
    Lung Cancer; 2016 Jun 20; 96():87-92. PubMed ID: 27133756
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL, Han G, Peng M, Weng YM, Yuan JP, Yang GF, Yu JM, Song QB.
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec 20; 37(6):864-872. PubMed ID: 29270745
    [Abstract] [Full Text] [Related]

  • 19. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
    Hirano S, Naka G, Takeda Y, Iikura M, Hayama N, Yanagisawa A, Amano H, Nakamura M, Nakamura S, Tabeta H, Sugiyama H.
    Chin Clin Oncol; 2016 Dec 20; 5(6):77. PubMed ID: 28061541
    [Abstract] [Full Text] [Related]

  • 20. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L, Sørensen JB.
    Anticancer Res; 2015 Nov 20; 35(11):6255-9. PubMed ID: 26504059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.